Survodutide

What Is Survodutide?

Survodutide is a synthetic peptide developed by Boehringer Ingelheim and Zealand Pharma to activate two separate hormone receptors simultaneously: the GLP-1 receptor, the same target as semaglutide, and the glucagon receptor, a distinct target tied to energy expenditure and liver fat metabolism. This dual-receptor design places it in the same broader category as tirzepatide and retatrutide, compounds built around the idea that combining receptor targets produces effects beyond what any single target achieves alone.

Survodutide is still investigational. It has not received FDA approval and is currently working through Phase 3 trials, called the SYNCHRONIZE program, across both obesity and metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease.

What Survodutide Is Being Researched For

• Body Weight

  A Phase 2 dose-finding trial in adults with obesity found survodutide produced dose-dependent reductions in body weight, with the highest tested dose reaching a mean reduction of nearly 15% at 46 weeks.^[1]

• Liver Disease (MASH)

  A separate Phase 2 trial in people with MASH and liver fibrosis found survodutide produced significantly higher rates of histologic improvement in liver disease compared to placebo, one of the stronger responses reported in this specific trial category to date.^[2]

• Type 2 Diabetes

  Beyond obesity and liver disease, research has also examined survodutide's effect on markers of insulin sensitivity and beta-cell function in people with type 2 diabetes or overweight.

How Survodutide Works

• Activating Two Receptors at Once

  Research points to survodutide binding to both the GLP-1 receptor and the glucagon receptor. The GLP-1 component relates to insulin release and appetite signaling, similar to other drugs in this broader class, while the glucagon component is thought to add an energy expenditure and direct liver-fat-reducing effect not present in GLP-1-only medications.^[1][2]

• Improving Liver Fat Through a Distinct Pathway

  Research points to the glucagon receptor component increasing lipid oxidation in the liver directly, which researchers have proposed as the mechanistic basis for survodutide's stronger-than-expected results in liver disease trials specifically.^[2]

• A Once-Weekly Signal

  Research points to survodutide's roughly week-long half-life supporting once-weekly dosing, consistent with other injectable peptides in this drug class.

Reconstitution and Handling

Because survodutide is not yet an approved medication, it's currently only available through clinical trials or as a research-grade compound sold as lyophilized powder, which requires reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Survodutide's defining feature is its dual glucagon/GLP-1 mechanism, which has shown meaningful results in both obesity and, notably, liver disease trials, an area where its added glucagon activity appears to offer a real advantage. It remains investigational, currently in Phase 3 trials, and has not completed the FDA approval process. Its strong Phase 2 MASH results are a particularly notable part of its research record worth watching as Phase 3 data matures.

Frequently Asked Questions

Sources and Research

1. le Roux CW, Zhang S, Aronne LJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173.
2. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319.